Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB

Health CarePharmaceuticals & Biotechnology
  • Price (SEK)230.50
  • Today's Change-3.50 / -1.50%
  • Shares traded388.00
  • 1 Year change38.44%
  • Beta1.9273
Data delayed at least 15 minutes, as of Aug 19 2019 08:23 BST.
More ▼

Profile data is unavailable for this security.

About the company

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-32.15m
  • Incorporated--
  • Employees8.00
  • Location
    Infant Bacterial Therapeutics ABGamla Brogatan 11STOCKHOLM 111 20SwedenSWE
  • Phone+46 841014555
  • Websitehttp://ibtherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Q linea AB1.53m-149.00m1.42bn61.00--3.25--926.98-7.81-7.810.078818.790.0054272.3371.1228,849.06-52.20---58.19---1,369.39---9,745.13--11.62-74,501.000.0021---28.93---89.09------
Hofseth Biocare ASA65.21m-89.22m1.45bn28.00--20.06--22.24-0.3054-0.30540.22250.22880.30661.886.41---41.96-43.71-75.19-77.7813.0121.43-136.85-187.250.6764-152.220.6531---8.29-0.7078-414.53---19.64--
IRLAB Therapeutics AB18.00k-75.97m1.55bn26.00--7.92--86,116.88-1.93-1.930.00054.840.0001--0.004720.00-41.94---44.95-------422,055.60-----274.250.0285---83.49---31.79------
Bonesupport Holding AB107.50m-191.44m1.74bn78.00--9.01--16.16-3.72-3.722.093.720.31330.57815.111,493,083.00-55.79---65.92--85.37---178.08--3.31-3,171.150.0581---25.27---36.89------
Surgical Science Sweden AB67.93m-5.07m1.76bn38.00--17.20319.5725.94-1.04-1.0413.9715.240.6873-0.17458.941,835,865.00-5.13---6.30--101.74---7.47--2.46-1,545.670.00--14.58---75.43------
Orphazyme A/S-143.67bn-143.67bn1.81bn57.00-----------------------------------------------------81.93------
Nordic Nanovector ASA0.00-362.94m1.91bn45.00--3.65-----6.75-6.750.008.860.00----0.00-54.52-34.38-62.03-38.09-------73,984.18----0.0125---100.00---14.96--48.77--
Calliditas Therapeutics AB0.00-136.37m2.05bn13.00--3.22-----6.64-6.640.0016.440.00----0.00-40.82---44.93--------------0.00-------52.14------
Orexo AB819.20m182.40m2.06bn130.0011.503.729.742.515.155.1523.1715.930.62690.8262.736,350,388.0013.96-1.4422.67-2.1082.6277.8022.27-2.281.91--0.4099--21.6612.77494.40---43.66--
Infant Bacterial Therapeutics AB0.00-32.15m2.54bn8.00--4.72-----2.86-2.860.0049.530.00----0.00-5.55-17.29-5.61-18.00-------28,727.13---32.950.00---100.00---12.31------
Immunovia AB (publ)286.60k-95.60m3.09bn46.00--7.10--10,767.46-5.02-5.020.01522.260.0008--16.866,368.89-26.39-17.94-27.94-18.78-15,583.15-5,071.06-33,355.42-13,304.19----0.0729--123.28-22.36-91.32--81.72--
Camurus AB57.77m-286.17m3.59bn117.00--7.48--62.20-6.45-6.451.3110.010.10360.58856.61614,617.00-51.32---64.52--84.36---495.33--2.61-501.220.0533---9.18---23.14------
Data as of Aug 19 2019. Currency figures normalised to Infant Bacterial Therapeutics AB's reporting currency: Swedish Krona SEK

Institutional shareholders

34.03%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 20181.05m9.70%
Swedbank Robur Fonder ABas of 31 May 2019660.69k6.09%
AMF Fonder ABas of 31 Dec 2018501.59k4.62%
Tredje AP-fondenas of 31 Dec 2018415.64k3.83%
Andra AP-fondenas of 31 Dec 2018263.50k2.43%
Nordic Cross Asset Management ABas of 14 Aug 2019242.88k2.24%
Norges Bank Investment Managementas of 31 Dec 2018205.04k1.89%
Catella Fondf�rvaltning ABas of 31 Jul 2019183.23k1.69%
AXA Investment Managers (Paris) SAas of 31 Dec 201885.00k0.78%
Norron ABas of 31 Jul 201981.30k0.75%
More ▼
Data from 31 Dec 2018 - 15 Aug 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.